News Search Results
Jan 26, 2026, 13:56 ET ZINZINO AB (PUBL): Zinzino announces merger of It Works! into the Zinzino family of businesses for increased distribution power in North America and Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales.It Works!, is a globally renowned direct sales company in the
More news about: Zinzino
Jan 26, 2026, 13:43 ET ZINZINO AB (PUBL): Zinzino announces merger of It Works! into the Zinzino family of businesses for increased distribution power in North America and Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales.It Works!, is a globally renowned direct sales company in the
More news about: Zinzino
Jan 26, 2026, 10:49 ET 2026 Edition Of The Stanford Emerging Technology Review Offers Policymakers And Business Leaders New Insights Into The Implications Of Frontier Technologies
Amy Zegart."Breakthroughs in artificial intelligence, biotechnology, quantum science, advanced materials, and space technologies are reshaping economies, societies and geopolitics at breathtaking speed. Never before
More news about: Hoover Institution at Stanford University
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
https://www.globenewswire.com/news-release/2026/01/20/3221521/0/en/Biotechnology-Market-Size-to-Surpass-USD-9-06-Trillion-by-2035.htmlLogo:
More news about: Equity Insider
Jan 26, 2026, 10:01 ET Biomaterials Market worth $68.93 billion by 2030 | MarketsandMarkets™
(Germany).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 26, 2026, 09:48 ET /C O R R E C T I O N -- SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD/
In the news release, Moyom Biotechnology Announces Strategic Partnership with WPP Group to Elevate Aphranel's "Poetics of Time" Brand Positioning, issued Jan. 26, 2026 by SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD over PR Newswire, we are advised by the company that the description of WPP was incorrect.
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
Jan 26, 2026, 08:56 ET PLT Appoints Pritesh Shetty as Director of Business Development, APAC
for OmniActive Health Technologies.Mr. Shetty was awarded a Bachelor of Science degree in Biotechnology from SIES College (Mumbai University) and a Master of Business Administration in Biotechnology Marketing from the Savitribai Phule Pune University's Department of Management Sciences.About
More news about: PLT Health Solutions
Jan 26, 2026, 08:50 ET Draper Awarded Part of Defense Microelectronics Contract Worth Up to $25 Billion
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Jan 26, 2026, 08:30 ET Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
an emerging biotechnology company focused on identifying genetically modified cells lines, and through joint venture and licensing agreements developing innovative cell-based therapies.About SGAustria Pte. Ltd.SGAustria, based in Singapore, is a leading biotechnology company specializing
More news about: Avant Technologies Inc.
Jan 26, 2026, 08:30 ET Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease
More news about: Immusoft
Jan 26, 2026, 07:45 ET BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
Notes may be made only by means of an offering memorandum.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jan 26, 2026, 07:04 ET Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson's Disease
NIJMEGEN, The Netherlands, Jan. 26, 2026 /PRNewswire/ -- Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative diseases, today announced a scientific collaboration with Radboud University
More news about: Mair Therapeutics
Jan 26, 2026, 07:00 ET Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech
More news about: Divamics
Jan 26, 2026, 07:00 ET Origin Agritech to Hold Business Update & Fiscal Year 2025 Earnings Conference Call on Monday, February 2 at 8 a.m. ET
first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Jan 26, 2026, 02:00 ET HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract
More news about: HanchorBio Inc.
Jan 25, 2026, 19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 25, 2026, 19:00 ET Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
BOSTON, Jan. 25, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that the first patient has been dosed in a global Phase 2b clinical
More news about: Argo Biopharmaceutical Co., Ltd
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
LinkedIn.5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jan 23, 2026, 08:30 ET Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
60 to 200 molecules synthesized and tested in each program.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 23:40 ET 晶泰科技賦能萊芒生物取得細胞療法重大成果，以1‰劑量CAR-T實現多位系統性紅斑狼瘡完全緩解出院
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術META 10展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology、Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。目前公司發展迅速，70% 高層次研發人員來自國內外名校並具有豐富的產業化經驗，多條研發管線進展順利。其中代謝增強型 CAR-T 細胞治療正在開展
More news about: 晶泰科技
Jan 22, 2026, 10:45 ET Medical Electrodes Market Surges to USD 5.2 Billion by 2033, Propelled by 5.5% CAGR - Verified Market Reports®
Global Laboratory Information Management System/LIMS Market Size By Deployment Type (On Premise, Cloud Based), By End User (Pharmaceuticals, Biotechnology), By Software Type (Sample Management, Data Management), By Application (Clinical Research, Quality Assurance), By Distribution Channel (Direct Sales,
More news about: Verified Market Reports
Jan 22, 2026, 10:30 ET Next-Generation Sequencing Market worth $29.53 billion by 2030 | MarketsandMarkets™
sequencing market in 2024.The next-generation sequencing market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, clinical and diagnostic laboratories, and other end users. Academic and research institutes held the largest share of the next-generation
More news about: MarketsandMarkets
Jan 22, 2026, 09:37 ET Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
wet-lab validation through Insilico's automated assay platforms.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 09:11 ET COGNIZIN® CITICOLINE NAMED "FUNCTIONAL INGREDIENT TO WATCH IN 2026" BY MINTEL & BLACK SWAN DATA, SHOWCASING ITS EXPLOSIVE GROWTH IN THE BRAIN HEALTH CATEGORY
— Cognizin® —About Kyowa Hakko USAKyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to
More news about: Kyowa Hakko U.S.A
Jan 22, 2026, 09:00 ET Global Biopharma Company Triples Research Commitment to Tishman Speyer and Breakthrough Properties' One Milestone at the Harvard Enterprise Research Campus, One of Boston's Most Anticipated New Developments
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties